Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients
- 437 Downloads
Insulin-like growth factor 1 receptor (IGF1R) represents a novel molecular target in non-small-cell-lung cancer (NSCLC). IGF1R and epidermal growth factor receptor (EGFR) activation are essential to mediate tumor cell survival, proliferation, and invasion. This study investigates the prognostic role of IGF1R and EGFR in surgically resected NSCLC.
Materials and methods
IGF1R and EGFR copy number gain (CNG) were tested by fluorescence in situ hybridization (FISH) and protein expression by immunohistochemistry (IHC) in 125 stage I–II–IIIA NSCLC patients.
Fourty-six tumors (40.3 %) were IGF1R FISH-positive (FISH+), and 76 (67.2 %) were EGFR FISH+. Tumors with concomitant IGF1R/EGFR FISH+ were observed in 34 cases (30.1 %). IGF1R and EGFR FISH+ were associated with SCC histology (p = 0.01 and p = 0.04, respectively). IGF1R and EGFR protein over-expression (IHC+) were detected in 45 (36.0 %) and 69 (55.2 %) cases, respectively. Tumors with concomitant IGF1R/EGFR IHC+ were detected in 31 (24.8 %) patients. IGF1R/EGFR FISH+ and IGF1R/EGFR IHC+ were significantly associated (χ2 = 4.02, p = 0.04). Patients with IGF1R/EGFR FISH+ and IGF1R/EGFR IHC+ were associated with shorter disease-free survival (DFS) (p = 0.05 and p = 0.05, respectively). Patients with concomitant IGF1R/EGFR FISH+/IHC+ had a worse DFS and overall survival (p = 0.005 and p = 0.01, respectively). The multivariate model confirmed that IGF1R/EGFR FISH+/IHC+ (hazard ratio (HR), 4.08; p = 0.01) and tumor stage (II–III vs I) (HR, 4.77; p = 0.003) were significantly associated with worse DFS.
IGF1R/EGFR FISH+ correlates with IGF1R/EGFR IHC+. IGF1R/EGFR FISH+/IHC+ is an independent negative prognostic factor for DFS in early NSCLC. These features may have important implications for future anti-IGF1R therapeutic approaches.
KeywordsIGF1R EGFR Non-small-cell-lung cancer Prognosis
The authors acknowledge the technical assistance of the Cytogenetics Core of the University of Colorado Cancer Center for all FISH analyses. The authors thank the patients who participated in this study. This work was supported in part by a grant from the Italian Association for Cancer Research (AIRC) to A.F. and from Umbria Association Against Cancer (AUCC) for IHC reagents.
Conflict of interest
The author(s) indicated no potential conflicts of interest.
- 11.Karp DD, Paz-Ares LG, Novello S et al (2009) Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27:2516–2522PubMedCrossRefGoogle Scholar
- 22.Makoto N, Hidetaka U, Soichi O et al (2011) Clinical significance of IGF1R expression in non-small-cell lung cancer. Clinical Lung cancer 13(2):136–142Google Scholar
- 23.Dziadziuszko R, Merrick DT, Witta SE et al (2010) Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non–small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 28(13):2174–2180PubMedCrossRefGoogle Scholar
- 24.Ludovini V, Bellezza G, Pistola L et al (2009) High coexpression of both insulin-like growth factor receptor-1(IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20:842–849PubMedCrossRefGoogle Scholar
- 33.Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187–220Google Scholar
- 39.Merrick DT, Dziadziuszko R, Szostakiewicz B et al. (2007) High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 25:18 s (Abstr 7550)Google Scholar
- 42.Van den Berg HW, Claffie D, Boylan M, McKillen J, Lynch M, McKibben B (1996) Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression. Br J Cancer 73:477–481PubMedCrossRefGoogle Scholar